A Phase 1b/2 Study of PCM-075 in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)

Trial Profile

A Phase 1b/2 Study of PCM-075 in Combination With Either Low-Dose Cytarabine or Decitabine in Subjects With Acute Myeloid Leukemia (AML)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Aug 2018

At a glance

  • Drugs PCM 075 (Primary) ; Cytarabine; Decitabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors TrovaGene
  • Most Recent Events

    • 03 Aug 2018 According to a TrovaGene media release, this trial have successfully completed treatment of 10 patients with PCM-075, 6 at the first dose level of 12 mg/m2 and 4 at the second dose level of 18 mg/m2, in combination with either low-dose cytarabine or decitabine.
    • 09 Jul 2018 According to a TrovaGene media release, the company is planning to initiate the Phase 2 segment (n=32) in the 2H 2018.
    • 09 Jul 2018 According to a TrovaGene media release, the company is planning to present data at the 60th annual American Society of Hematology (ASH) conference.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top